Clinical cancer genomics: How soon is now?

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 319-327

  Taylor, Barry S ^a,b   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; genomics; genotyping; mutation detection; personalized therapy; sequencing

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMATINIB; K RAS PROTEIN; NILOTINIB; TRANSCRIPTOME;

CANCER EPIDEMIOLOGY; CANCER SUSCEPTIBILITY; CANCER TISSUE; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COLORECTAL CARCINOMA; DNA SEQUENCE; FAMILIAL CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE FUSION; GENE MUTATION; GENOMICS; GENOTYPE; HUMAN; HUMAN GENOME; PRIORITY JOURNAL; REVIEW; TUMOR CLASSIFICATION; TUMOR GENE; TUMOR SUPPRESSOR GENE;

EID: 78650001387     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2794     Document Type: Review

References (87)

1. Ferlay J, Shin HR, Bray F, et al., GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC CancerBase 2010; No. 10:.
2. Stratton MR, Campbell PJ, Futreal PA,. The cancer genome. Nature 2009; 458: 719-724.
3. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
4. Boveri T,. Concerning the Origin of Malignant Tumours. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 2008.
5. Knudson AG Jr,. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
6. Bell DW,. Our changing view of the genomic landscape of cancer. J Pathol 2010; 220: 231-243.
7. Chin L, Gray JW,. Translating insights from the cancer genome into clinical practice. Nature 2008; 452: 553-563.
8. Feero WG, Guttmacher AE, Collins FS,. Genomic medicine-an updated primer. N Engl J Med 2010; 362: 2001-2011.
9. Shendure J, Ji H,. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-1145.
10. Ding L, Ellis MJ, Li S, et al., Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
11. Jones S, Zhang X, Parsons DW, et al., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
12. Lee W, Jiang Z, Liu J, et al., The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-477.
13. Ley TJ, Mardis ER, Ding L, et al., DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
14. Mardis ER, Ding L, Dooling DJ, et al., Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
15. Parsons DW, Jones S, Zhang X, et al., An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
16. Pleasance ED, Cheetham RK, Stephens PJ, et al., A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-196.
17. Pleasance ED, Stephens PJ, O'Meara S, et al., A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-190.
18. Sjoblom T, Jones S, Wood LD, et al., The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
19. Wood LD, Parsons DW, Jones S, et al., The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
20. Clark MJ, Homer N, O'Connor BD, et al., U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 2010; 6: e1000832.
21. Shah SP, Morin RD, Khattra J, et al., Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
22. Morin RD, Johnson NA, Severson TM, et al., Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
23. Druker BJ, Talpaz M, Resta DJ, et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
24. Krause DS, Van Etten RA,. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
25. Hirota S, Isozaki K, Moriyama Y, et al., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. (Pubitemid 28067289)
26. Demetri GD, von Mehren M, Blanke CD, et al., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
27. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
28. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
29. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
30. Flaherty KT, Puzanov I, Kim KB, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
31. Koivunen JP, Mermel C, Zejnullahu K, et al., EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283.
32. Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
33. Mellinghoff IK, Wang MY, Vivanco I, et al., Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-2024.
34. Van Cutsem E, Kohne CH, Hitre E, et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
35. Bean J, Brennan C, Shih JY, et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
36. Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
37. Stommel JM, Kimmelman AC, Ying H, et al., Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-290.
38. Balak MN, Gong Y, Riely GJ, et al., Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12: 6494-6501.
39. Knight ZA, Lin H, Shokat KM,. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10: 130-137.
40. Dias-Santagata D, Akhavanfard S, David SS, et al., Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010; 2: 146-158.
41. MacConaill LE, Campbell CD, Kehoe SM, et al., Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4: e7887.
42. Thomas RK, Baker AC, Debiasi RM, et al., High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
43. Janakiraman M, Vakiani E, Zeng Z, et al., Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70: 5901-5911.
44. Sharma SV, Bell DW, Settleman J, et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
45. Gnirke A, Melnikov A, Maguire J, et al., Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009; 27: 182-189.
46. Hodges E, Xuan Z, Balija V, et al., Genome-wide in situ exon capture for selective resequencing. Nat Genet 2007; 39: 1522-1527.
47. Choi M, Scholl UI, Ji W, et al., Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 2009; 106: 19096-19101.
48. Shah SP, Kobel M, Senz J, et al., Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360: 2719-2729.
49. Jones S, Wang TL, Shih IM, et al., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; (in press).
50. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; DOI: 10.1056/NEJMoa1008433: 1-12.
51. Leary RJ, Kinde I, Diehl F, et al., Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010; 2: 20ra14.
52. Maher CA, Kumar-Sinha C, Cao X, et al., Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.
53. Maher CA, Palanisamy N, Brenner JC, et al., Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci USA 2009; 106: 12353-12358.
54. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
55. Tomlins SA, Rhodes DR, Perner S, et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
56. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al., Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793-798.
57. Bollag G, Hirth P, Tsai J, et al., Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
58. Stalder L, Muhlemann O,. The meaning of nonsense. Trends Cell Biol 2008; 18: 315-321.
59. Weinberg RA,. Tumor suppressor genes. Science 1991; 254: 1138-1146.
60. Levin JZ, Berger MF, Adiconis X, et al., Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol 2009; 10: R115.
61. He Y, Wu J, Dressman DC, et al., Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 2010; 464: 610-614.
62. Legros F, Malka F, Frachon P, et al., Organization and dynamics of human mitochondrial DNA. J Cell Sci 2004; 117: 2653-2662.
63. Thomas RK, Nickerson E, Simons JF, et al., Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006; 12: 852-855.
64. Campbell PJ, Pleasance ED, Stephens PJ, et al., Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 2008; 105: 13081-13086.
65. McCaughan F, Dear PH,. Single-molecule genomics. J Pathol 2010; 220: 297-306.
66. Alimonti A, Carracedo A, Clohessy JG, et al., Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42: 454-458.
67. Stephens PJ, McBride DJ, Lin ML, et al., Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
68. Visel A, Zhu Y, May D, et al., Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010; 464: 409-412.
69. Ashley EA, Butte AJ, Wheeler MT, et al., Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525-1535.
70. Ng SB, Turner EH, Robertson PD, et al., Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009; 461: 272-276.
71. Ng SB, Buckingham KJ, Lee C, et al., Exome sequencing identifies the cause of a Mendelian disorder. Nat Genet 2010; 42: 30-35.
72. Ng SB, Bigham AW, Buckingham KJ, et al., Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 2010; (in press).
73. Lupski JR, Reid JG, Gonzaga-Jauregui C, et al., Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362: 1181-1191.
74. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
75. International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010; 464: 993-998.
76. Jones S, Hruban RH, Kamiyama M, et al., Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
77. Koboldt DC, Ding L, Mardis ER, et al., Challenges of sequencing human genomes. Brief Bioinform 2010; (in press).
78. McPherson JD,. Next-generation gap. Nat Methods 2009; 6: S2-5.
79. Barretina J, Taylor BS, Banerji S, et al., Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715-721.
80. Boehm JS, Zhao JJ, Yao J, et al., Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-1079.
81. Iorns E, Lord CJ, Turner N, et al., Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007; 6: 556-568.
82. Zender L, Xue W, Zuber J, et al., An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135: 852-864.
83. Kim C, Paik S,. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 2010; 7: 340-347.
84. Taylor BS, Schultz N, Hieronymus H, et al., Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
85. ten Bosch JR, Grody WW,. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn 2008; 10: 484-492.
86. Beaudet AL, et al., Which way for genetic-test regulation? Leave test interpretation to specialists. Nature 2010; 466: 816-817.
87. Javitt G,. Which way for genetic test regulation? Assign regulation appropriate to the level of risk. Nature 2010; 466: 817-818.